A Phase II open-label multicentreTrial of first-line Oxaliplatin-based chemotherapy combined with ABP 980 (Biosimilar Trastuzumab) in patients with advanced Gastric or gastro-Esophageal juncTion (GEJ) cancer, HER2-positive
Latest Information Update: 08 Sep 2021
At a glance
- Drugs Capecitabine (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 08 Sep 2021 New trial record